FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

GH Max Output Protocol

GH Optimizationadvanced
23
Share
ペプチド

4

平均日用量mcg

3,814

レベル

advanced

追加

May 16, 2026

概要

The GH Max Output Protocol is an advanced-level growth hormone optimization stack that combines four synergistic secretagogues and releasing hormones to maximize pulsatile GH output throughout the day. This is the most comprehensive GH protocol available, designed for experienced users who have already responded well to simpler GH peptide stacks and are seeking elite-level hormonal optimization for muscle growth, fat loss, recovery, and anti-aging. CJC-1295 at 2000mcg three times weekly provides a sustained elevation of baseline growth hormone releasing hormone (GHRH) signaling. As a modified GHRH analogue with extended half-life via Drug Affinity Complex (DAC) technology, it creates a steady amplification of GH pulses over several days per injection, raising the floor from which all other secretagogues operate. Ipamorelin at 300mcg twice daily triggers acute GH pulses by mimicking ghrelin at the pituitary. Its selectivity means clean GH release without unwanted cortisol or prolactin elevation. Twice-daily dosing creates multiple GH spikes that mirror youthful secretion patterns. Tesamorelin at 2000mcg daily is an FDA-approved GHRH analogue that powerfully stimulates anterior pituitary somatotrophs. It provides a strong GHRH signal distinct from CJC-1295, and clinical trials have demonstrated significant reductions in visceral fat and improvements in IGF-1 levels. Sermorelin at 500mcg on a 5-days-on/2-days-off schedule provides additional GHRH stimulation through a slightly different receptor binding profile. The cycling schedule prevents receptor desensitization and maintains pituitary sensitivity. The combined effect of layered GHRH signals (CJC-1295, Tesamorelin, Sermorelin) with a ghrelin-mimetic pulse trigger (Ipamorelin) produces GH output that approaches youthful peak levels while maintaining the natural pulsatile pattern that prevents receptor downregulation. Protocol Notes: Ipamorelin doses should be taken on an empty stomach—morning upon waking and before bed. Tesamorelin and Sermorelin are best administered in the evening. CJC-1295 (with DAC) injection days should be spaced evenly. This stack requires regular IGF-1 and glucose monitoring. It is suited for advanced users over 35 seeking maximum anabolic and recovery support. Typical cycles run 12-16 weeks with comprehensive bloodwork at baseline, mid-cycle, and post-cycle.

投与プロトコル

2,000 mcg

1回の投与あたり

300 mcg

1回の投与あたり

2,000 mcg

1回の投与あたり

500 mcg

1回の投与あたり

目標と証拠

証拠ランク:community

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。